The slimming injections They have gone from being a virtually unknown treatment to becoming one of the most discussed topics in medical consultations, the media, and social networks. In just a few years, These weight loss medications Hormone-based therapies have gone from treating only type 2 diabetes to occupying a central place in the treatment of obesity.
The growing interest is not only explained by the significant weight loss that they can achieve in certain patients, but also because of the economic and social impact that they are generating. While in countries like India access to them is becoming cheaper thanks to the emergence of generics, in Spain and the rest of Europe the debate focuses on price, fairness and the risk of turning them into a quick fix without adequate control.
What are weight loss injections and how do they work?
The latest generation of slimming injections belong primarily to the group of GLP-1 receptor agonists and, in some cases, combinations of several hormonal pathways. These are drugs that mimic the action of an intestinal hormone, GLP-1, involved in the regulation of blood sugar and appetite.
They are available in Spain several active ingredients of this family: liraglutide, semaglutide, dulaglutide and tirzepatide in obesityAll are administered subcutaneously using pre-filled pens, with schedules that can be daily (as with liraglutide) or weekly (semaglutide, dulaglutide and tirzepatide).
These medications were initially developed for the type 2 diabetes managementbecause they increase insulin release when glucose levels rise and reduce glucagon secretion. Furthermore, they slow gastric emptying and create a longer-lasting feeling of fullness, leading to eating less almost automatically.
Precisely that combination of better glycemic control and reduced appetite This is what caught the attention of clinical trials and prompted specific studies on obesity. Today, the European Medicines Agency recognizes that, in certain patient profiles, weight loss can be significant when treatment is accompanied by dietary and lifestyle changes.
Main brands and authorized uses in Spain
In the Spanish market, the same active ingredients can be marketed under different brands depending on the indication. Liraglutide, for example, is sold as Victoza when prescribed for diabetes and as Saxenda when the goal is to achieve weight reduction in cases of obesity or overweight with associated risk factors.
Semaglutide is distributed as Ozempic for the treatment of type 2 diabetes, while its specific formulation for weight loss is marketed under the name of wegovyTirzepatide, meanwhile, has positioned itself as a dual-action medication, registered as Mounjaro and valid for both glycemic control and weight management, using the same doses in both indications.
Of all these drugs, only some have express indication for weight lossSaxenda (liraglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide) are used in the context of obesity or overweight with comorbidities. The OCU (Spanish Consumers' Organization) reminds users that all of these medications require a prescription and that, when used for weight loss, they are not covered by public healthcare in Spain, unlike their use in diabetes.
This nuance is important, because the financing of the National Health System In practice, its use is limited to diabetic patients in the case of Ozempic. In community pharmacies, a pen of this medication can cost around 128 euros, but with a prescription from the National Health Service, the patient's co-payment is reduced to just a few euros, which has driven up demand among certain groups.
International expansion and debate on access
Globally, weight-loss injections have generated a multi-billion dollar market that continues to grow. Recent studies suggest that one in eight adults In the United States, she is currently taking a GLP-1 drug, according to a survey by the health research group KFF. The oral version of Wegovy alone has reportedly accumulated hundreds of thousands of prescriptions in a matter of months.
In countries like India, the arrival of drugs like Mounjaro and the patent expiration The availability of semaglutide has completely changed the landscape. More than 50 generic versions are now marketed there at prices up to 70% lower than the originals, which has greatly expanded access among the population, not always under strict medical supervision.
Indian regulators estimate that the obesity drug market could approach 80.000 billion rupees within a few years, with sales of Mounjaro having soared since its launch and a growing supply of semaglutide generics. This combination of High social interest, falling prices, and a strong marketing campaign has raised concerns about possible misuse.
In Europe, the situation is very different. The European Union maintains the semaglutide patent protection until 2031This hinders the arrival of generic drugs and limits price drops. Even so, international pressure and the example of Asian countries are fueling the debate on how to guarantee equitable access without overwhelming public budgets.
Impact in Spain: prices, financing and fairness
In Spain, the debate surrounding weight-loss injections lies at the intersection of economics, public health, and regulation. On the one hand, their effectiveness is acknowledged. effectiveness in obesityOn the other hand, there are concerns about the cost and the possibility of mass use for purely aesthetic purposes.
The manufacturer Novo Nordisk recently announced price reductions of its Wegovy and Ozempic presentations in the Spanish market. At the highest dose of Wegovy, the reduction reaches approximately 17,6%, placing the price at around €223,64 per pen. Ozempic has also seen price reductions, although this medication is covered by the National Health System for people with type 2 diabetes.
Even with these adjustments, experts point out that the real impact on patients It depends on several factors: the maintenance of patent protection in the European Union, regulatory decisions on new indications, and public funding criteria. The entry of generics into other markets could put downward pressure on international prices, but this does not imply an immediate change in access in Spain.
Endocrinologists and scientific societies insist that any expansion of funding for patients with obesity should be accompanied by clear prescription criteriaClinical monitoring, secure dispensing protocols, and measures to prevent shortages are essential. Without this framework, the risk is that the system will incur a very high cost without guaranteeing that treatment reaches those who need it most.
Obesity in Spain: the “silent pandemic”
This entire debate is framed within a reality that the World Health Organization constantly emphasizes: obesity is a chronic disease and globally, its prevalence has skyrocketed in recent decades. It is estimated that around one in eight people worldwide has a body mass index equal to or greater than 30 kg/m².
In Spain, data from the National Institute of Statistics indicate that approximately 15,2% of adults Obesity is prevalent, affecting more than six million people. However, the official recognition of this condition is not keeping pace: obesity is still not included in the National Health System's Catalogue of Chronic Diseases, despite its impact on the development of diabetes, hypertension, cardiovascular diseases, and many other complications.
This gap between scientific evidence and administrative fit has direct consequencesIn practice, only obese patients who also suffer from type 2 diabetes have access to funded therapeutic access to certain injectable drugs, mainly Ozempic, while the rest must bear the full cost of treatments such as Saxenda or Wegovy.
Pharmacists and nutrition specialists argue that considering obesity as a chronic disease for administrative purposes would allow for the design of prevention and treatment strategies more coherent, with a rational use of these medicines and better planning of health spending.
Weight loss injections: a tool, not a miracle
Despite the hype surrounding them, experts agree that slimming injections are not a “magic potion” that can resolve excess weight on its own. It is a powerful tool that only fits within a comprehensive medical approach, based on structural lifestyle changes.
Leading endocrinologists insist that The prescription is not the treatmentRather, it's just one component of a much broader plan that includes healthy eating, regular physical activity, adequate rest, and stress management. In practice, many patients tend to place all the responsibility on the medication and neglect these other essential elements, which contributes to the rebound effect once they stop taking it.
In fact, it has been observed that, without parallel work on habits, some users quickly regain weight upon discontinuing the injections, which fuels a treatment restart cycleThis pattern reminds us that obesity is a chronic condition and that the goal should not only be to lose weight before a specific date, but to maintain the results in the long term.
Consumer organizations like the OCU emphasize that these medications should be reserved for cases where there is a clinical indication According to the guidelines: established obesity or overweight with risk factors, always under professional supervision, with clear information on the safety profile and realistic expectations of weight loss.
Side effects and safety: what you should keep in mind
Like any powerful medication, weight loss injections can cause Adverse effectsThe most common side effects are digestive: nausea, vomiting, diarrhea, or constipation, especially during the first few weeks of treatment or when the dose is increased. These symptoms usually improve over time, but they can be bothersome.
Furthermore, there is concern about the loss of muscle mass This is associated with rapid weight loss, which has led many specialists to emphasize the importance of strength training and adequate protein intake during therapy. Maintaining muscle mass is key to preserving metabolism and reducing the risk of long-term injury or frailty.
In terms of large-scale safety, some health agencies and organizations have begun collecting data on potentially more serious complications, such as acute pancreatitisBetween 2007 and 2025, more than a thousand cases associated with the use of these drugs were reported in the United Kingdom, with about twenty deaths, while other countries, such as Brazil, have also reported deaths related to this adverse reaction.
Available clinical studies offer mixed results: some suggest a slight increase in the risk of pancreatitis, while others find no significant differences compared to control groups. Factors such as obesity itself, diabetes, or very rapid weight loss may play a role, which is why research is currently underway. possible genetic predispositions that make certain patients more vulnerable. In any case, it is recommended to discontinue treatment if pancreatitis is confirmed and to exercise extreme caution in people with a history of the condition.
Off-label use and social pressure
Beyond diagnosed obesity, the media success of weight loss injections has encouraged their use for purely aesthetic purposes or to reach a specific weight in a short period, something that worries authorities and scientific societies. The Pan American Health Organization has called for strengthened pharmacovigilance and warnings about the risks of informal channels or without a prescription.
In some countries, intensive weight loss programs have become popular before weddings or other social events, integrating GLP-1 treatments in “transformation” packages which previously focused solely on aesthetics, skincare, or makeovers. Although this trend has been particularly pronounced outside of Europe, it reflects a growing social pressure to conform to certain physical standards.
This same phenomenon is also beginning to be seen in Europe, where messages on social media are proliferating that present these drugs as the fast track to change sizeTherefore, organizations such as the OCU and drug agencies emphasize that these are not beauty products, but treatments that should only be used under health supervision and according to approved indications.
When consumption skyrockets for aesthetic reasons, it further aggravates the supply shortage problemDrugs such as Ozempic, Saxenda, and Trulicity have suffered stock shortages, forcing authorities to reiterate that priority should be given to patients with type 2 diabetes or obesity who have a clearly justified prescription.
Where is the debate in Europe headed?
In the coming years, the debate on weight loss injections in Spain and the rest of Europe will revolve around several key issues: equal accesseconomic sustainability, long-term security and a model of care for obesity as a chronic disease, and not as a mere image problem.
If prices are substantially reduced in the future or generic versions are introduced once the patents expire in the European Union, it is likely that the market will reopen. debate on its public fundingEven so, cost-effectiveness criteria, the definition of the target population, real-life observed health outcomes, and budgetary capacity will continue to be determining factors for any policy change.
At the same time, demand is growing for more health education Regarding these treatments: explain who can truly benefit, what their limitations are, what risks they entail, and why lifestyle remains the essential component of any weight-loss plan. Without this information, the "miracle drug" narrative easily takes hold, leading to patient frustration when expectations are not met.
For many specialists, the challenge is not only deciding how many people will be able to access the weight-loss injections, but to ensure that its use is responsibleThis requires rigorous medical monitoring and a combination of nutritional, psychological, and physical activity interventions. Ultimately, the goal is for this new generation of drugs to be part of a comprehensive strategy against obesity, not simply a haphazard medicalization of weight.
